Filing Flows › TScan Therapeutics (TCRX) › Stock forecast & fair value
TScan Therapeutics (TCRX) stock forecast and price target
TScan Therapeutics (TCRX) trades at $0.19. The analysts' price target is $1.00 (+432%).
TScan Therapeutics' latest quarter
TScan Therapeutics, Q2 2026: revenue $1.1M (-66% year over year), net loss $30.4M, operating cash flow −$27.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for TCRX stock?
The analysts' 12-month target is $1.00, +432% from $0.19. The average rating is none.
Does TScan Therapeutics usually beat earnings estimates?
It beat the consensus EPS estimate in 50% of the quarters on record.
Is TCRX stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.